Sovaldi
SOVALDI is a groundbreaking hepatitis C (Hep C) treatment. Clinical studies have shown that SOVALDI combination therapy can be effective for people with genotypes 1, 2, 3, and 4.

See below for information on the results achieved by patients in clinical studies:
Halaven is an anti-cancer ("antineoplastic"or "cytotoxic") chemotherapy drug. This medication is classified as a "non-taxane microtubule inhibitor". (For more detail, see “How Halaven Works” below)
SOVALDI combination therapy cure rates in clinical studies
The table below includes the percentages of patients, in SOVALDI clinical studies, who were cured of the Hep C virus. Cure means the Hep C virus is not detected in the blood when measured 3 months after treatment is completed.

GENOTYPE DURATION TREATMENT CURE RATE
1 OR 4 12 WEEKS SOVALDI + ribavirin+ peginterferon alfa 89% / 96%
2 12 WEEKS SOVALDI + ribavirin 93%
3 24 WEEKS SOVALDI + ribavirin 84%


Clinical study details


CURE RATES
SOVALDI-clinical-study-details-geno-type-1

Genotype 1 (GT1) and Genotype 4 (GT4):
In a clinical study of 327 patients with Hep C genotypes 1, 4, 5, and 6 without prior Hep C treatment taking SOVALDI + ribavirin + peginterferon alfa for a treatment duration of 12 weeks, the cure rate was 90% (295 out of 327 patients studied). The cure rate was 89% (261 out of 292 patients studied) for GT1 and 96% (27 out of 28 patients studied) for GT4.


CURE RATES
SOVALDI-clinical-study-details-geno-type-1

Genotype 2 (GT2) and Genotype 3 (GT3):
In a clinical study of patients with Hep C genotypes 2 and 3 with and without prior Hep C treatment taking SOVALDI + ribavirin, the cure rate for patients with GT2 was 93% (68 out of 73 patients studied) and the cure rate for patients with GT3 was 84% (210 out of 250 patients studied).

Other Hep C clinical studies in GT2 and GT3 patients with and without prior Hep C treatment:


  • For patients with GT2, cure rates ranged from 82% to 95% for a treatment duration of 12 or 16 weeks of SOVALDI + ribavirin. For GT2, the approved treatment duration is 12 weeks of SOVALDI + ribavirin


  • For patients with GT3, cure rates ranged from 30% to 62% for a treatment duration of 12 or 16 weeks of SOVALDI + ribavirin. For GT3, the approved treatment duration is 24 weeks of SOVALDI + ribavirin